This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases, Other  • Statistics and Research Methods  • Hypertension  • Cardiovascular System, Other  • Alert me on articles by topic

Mike Mitka

JAMA. 2007;297:456-457.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Seeking to enable researchers and clinicians to share experiences and ideas regarding a relatively rare—and, so far, incurable—condition, the National Institutes of Health (NIH) sponsored its first international meeting on pulmonary arterial hypertension.

The December gathering in Bethesda, Md, was designed to be "a forum for learning, scientific discussion, and development of new collaborations that will further the understanding of pulmonary hypertension and hopefully lead to treatment advances for the disease," said Roberto Machado, MD, an investigator with the Vascular Medicine Branch of the NIH's National Heart, Lung, and Blood Institute (NHLBI).

Smooth muscle hypertrophy and narrowing of the lumen of the pulmonary artery are hallmarks of pulmonary arterial hypertension, a serious lung and heart disorder. (Photo credit: JAMA. 2000;284:3160-3168)

Pulmonary arterial hypertension, or continuous high blood pressure in the blood vessels of the lungs, is a disabling and ultimately fatal disease affecting people of all ages. . . . [Full Text of this Article]

IMPROVED TREATMENT